Post-biopsy hemorrhage describes the accumulation of blood products in the prostate gland and periprostatic tissue following prostate biopsy, and is the most important artifact source that severely compromises multiparametric prostate MRI. Following TRUS-guided systematic biopsy, MRI-detectable hemorrhage develops in 80-100% of patients. Marked hyperintensity on T1-weighted sequences due to methemoglobin is the characteristic finding — this T1 bright signal can be observed in diffuse or focal pattern in both peripheral zone and transition zone. Post-biopsy hemorrhage creates hypointense signal on T2-weighted sequences mimicking prostate cancer; it can lead to false positive findings on DWI due to T2 shine-through or true diffusion restriction. PI-RADS v2.1 guidelines strongly recommend that mpMRI should be performed at least 6 weeks (ideally 8 weeks) after biopsy — this is the minimum time needed for resolution of hemorrhage products. Early MRI can lead to masking of lesions, incorrect PI-RADS scores, and unnecessary repeat biopsy. The MRI appearance of hemorrhage is time-dependent: deoxyhemoglobin dominates in the acute phase (0-3 days), methemoglobin in the subacute phase (3 days-6 weeks), and hemosiderin in the chronic phase (>6 weeks).
Age Range
50-75
Peak Age
65
Gender
Male predominant
Prevalence
Common
In TRUS-guided systematic prostate biopsy, typically 10-12 (sometimes 20+) cores are obtained using an 18G biopsy needle. Each needle pass creates mechanical vascular damage in the prostate parenchyma and periprostatic venous plexuses (Santorini venous plexus). Blood extravasates along biopsy tracts and surrounding tissue forming hematomas. Extravascular blood undergoes time-dependent enzymatic degradation: (1) Acute phase (0-72 hours): intracellular oxygenated hemoglobin converts to deoxyhemoglobin — deoxyhemoglobin is paramagnetic causing T2* shortening; isointense on T1, hypointense on T2. (2) Subacute phase (3 days-6 weeks): deoxyhemoglobin oxidizes to methemoglobin — methemoglobin is a potent paramagnetic agent that dramatically shortens T1 relaxation; creates characteristic hyperintensity on T1. Intracellular methemoglobin (early subacute) is hypointense on T2, extracellular methemoglobin (late subacute) is hyperintense on T2. (3) Chronic phase (>6 weeks): hemoglobin converts to hemosiderin and ferritin — superparamagnetic iron compounds cause marked T2* shortening and susceptibility artifact. Post-biopsy hemorrhage on DWI can create false positive findings through two mechanisms: (a) T2 shine-through — T2-hyperintense blood products appear bright on DWI but also show high signal on ADC map (not true restriction); (b) Blood clot and cellular debris density can cause true diffusion restriction.
The coexistence of T1-hyperintense + T2-hypointense area (T1-T2 discordance) is a pathognomonic sign for subacute hemorrhage. In adenocarcinoma, T2 hypointensity is present but T1 signal is normal (isointense). This T1-T2 discordance is the most reliable way to recognize post-biopsy hemorrhage and emphasizes the need for careful evaluation of pre-contrast T1 sequence in every prostate mpMRI.
Marked hyperintensity is observed in the prostate gland on T1-weighted sequences. In the subacute phase (3 days-6 weeks), T1 bright signal from methemoglobin is characteristic. Distribution pattern may be diffuse (entire gland), focal (specific region), or linear (along biopsy tracts). Detection of this hyperintensity on pre-contrast T1 sequence is the most reliable indicator of post-biopsy hemorrhage. Bilateral peripheral zone and transition zone involvement may occur. Pre-contrast T1 must be evaluated to avoid confusion with T1-hypointense enhancement.
Report Sentence
Marked hyperintensity is identified in the prostate gland [location]/diffusely on pre-contrast T1-weighted sequence, consistent with subacute hemorrhage related to recent biopsy.
Hypointensity is observed in the hemorrhagic area on T2-weighted sequences and can mimic prostate cancer. Deoxyhemoglobin (acute) and intracellular methemoglobin (early subacute) produce hypointense signal on T2. Hemosiderin deposition (chronic phase) causes marked T2 hypointensity. Post-biopsy T2 hypointensity may be indistinguishable from cancer lesion in the peripheral zone — cross-reference with T1 sequence is mandatory. An area hypointense on T2 but hyperintense on T1 points to hemorrhage.
Report Sentence
Hypointensity is observed in the [location] on T2-weighted sequence, consistent with post-biopsy hemorrhage when combined with T1 hyperintensity; tumor cannot be excluded in this area, and follow-up MRI after 6-8 weeks is recommended.
Bright signal on DWI may be observed in the hemorrhagic area and can be confused with adenocarcinoma. This bright signal can be produced by two mechanisms: (1) T2 shine-through: high T2 signal of extracellular methemoglobin reflects on DWI — differentiated from true restriction by high signal on ADC map; (2) True diffusion restriction: density of blood clot and cellular debris truly restricts water diffusion — also gives low signal on ADC. This second mechanism is the most dangerous mimicking feature of post-biopsy hemorrhage because it cannot be distinguished from adenocarcinoma by DWI/ADC.
Report Sentence
Increased signal on DWI in the [location] may be consistent with T2 shine-through or true diffusion restriction due to post-biopsy hemorrhage; follow-up MRI after 6-8 weeks is recommended for definitive exclusion of tumor.
On T1-weighted sequences, linear hyperintense areas following the path of the biopsy needle are observed. This biopsy tract hemorrhage is conspicuous in a linear pattern extending from prostate capsule toward the center. Multiple tracts may be simultaneously visible (corresponding to 10-12 core biopsy). Diffuse hemorrhage spread between tracts and surrounding parenchyma may also accompany. This linear pattern differs from the focal/round morphology of tumor and is an important clue for recognizing hemorrhage.
Report Sentence
Linear hyperintense tracts extending from the capsule toward the center are identified in the prostate gland on T1-weighted sequence, consistent with biopsy tract hemorrhage.
Heterogeneous echotexture and hyperechoic or hypoechoic areas may be observed in the prostate gland after biopsy on TRUS. Acute hemorrhage appears hyperechoic (bright), while organized hematoma may be hypoechoic. Biopsy tracts may be visible as hypoechoic linear areas. Periprostatic hemorrhage/hematoma may also accompany. TRUS findings are nonspecific and not reliable for hemorrhage-cancer differentiation — mpMRI is the reference imaging.
Report Sentence
Heterogeneous echotexture changes are observed in the prostate gland after biopsy on TRUS.
Criteria
First 72 hours after biopsy. Deoxyhemoglobin dominates. Isointense on T1, hypointense on T2/T2*.
Distinct Features
T1 hyperintensity is not yet prominent — hemorrhage can be missed on T1 in this phase. T2/T2* hypointensity is present. Blooming artifact may be seen on GRE/SWI sequences. As at least 6 weeks waiting is needed clinically, MRI in acute phase is generally not indicated.
Criteria
Between 3rd day and 6th week after biopsy. Methemoglobin dominates. Marked hyperintensity on T1 (pathognomonic). T2 hypointense in early subacute, T2 hyperintense in late subacute.
Distinct Features
Classic T1 bright signal is most prominent in this phase. DWI false positive risk is highest (T2 shine-through and/or true restriction). PI-RADS v2.1's recommendation to wait 6-8 weeks is aimed at preventing this phase from compromising mpMRI interpretation. Evaluating enhancement pattern in the hemorrhage area on contrast-enhanced MRI is difficult.
Criteria
More than 6-8 weeks after biopsy. Hemosiderin/ferritin deposition. T1 signal begins to normalize, focal hypointensity on T2/T2* may persist.
Distinct Features
T1 hyperintensity has generally resolved. Residual focal T2 hypointensity may remain — can be confused with cancer but normal T1 and normal DWI favor hemorrhagic residue. Hemosiderin blooming may be observed on GRE/SWI. mpMRI interpretation is most reliable in this phase.
Distinguishing Feature
In adenocarcinoma, T1 signal is normal (isointense) but marked focal T2 hypointensity and true diffusion restriction on DWI (ADC low) are seen. In post-biopsy hemorrhage, T1 hyperintensity (methemoglobin) is present — this is the cardinal differentiating point. Hemorrhage resolves over time (regression on 6-8 week follow-up MRI) while adenocarcinoma persists. Biopsy history and timing correlation are essential.
Distinguishing Feature
In prostatitis, diffuse T2 hypointensity and increased enhancement are seen while T1 signal is normal (no hyperintensity). In post-biopsy hemorrhage, T1 hyperintensity is pathognomonic. Prostatitis is symptomatic (pain, dysuria) while post-biopsy hemorrhage is generally asymptomatic or minimally symptomatic. Prostatitis may improve with treatment; hemorrhage resolves spontaneously.
Distinguishing Feature
In abscess, T2-hyperintense center + hypointense rim and marked focal diffusion restriction on DWI (in cavity center) are seen. The abscess cavity shows hypointense to intermediate T1 signal, while in post-biopsy hemorrhage T1 hyperintensity has diffuse or linear distribution. Abscess shows rim enhancement while hemorrhage does not show organized enhancement pattern. Abscess presents with fever and systemic infection signs; hemorrhage is generally afebrile.
Urgency
routineManagement
conservativeBiopsy
Not NeededFollow-up
6-monthPost-biopsy hemorrhage is a benign and self-limited condition requiring no specific treatment. Its clinical significance lies in compromising mpMRI interpretation: (1) PI-RADS v2.1 guidelines strongly recommend waiting at least 6 weeks (ideally 8 weeks) after biopsy for mpMRI; (2) If early MRI has been obtained, T1 sequence should be carefully evaluated to mark hemorrhagic areas and T2/DWI findings in these areas should be interpreted with caution; (3) When T1-hyperintense + T2-hypointense area is detected, DWI restriction in this region should be assessed as hemorrhage rather than cancer and follow-up MRI after 6-8 weeks should be recommended; (4) If persistent T2 hypointensity and DWI restriction are present on MRI obtained after hemorrhage resolution, biopsy indication is strengthened; (5) Pre-biopsy MRI protocol (mpMRI before biopsy) completely prevents hemorrhage artifact and provides optimal assessment — current guidelines recommend mpMRI before biopsy.
Post-biopsy hemorrhage is the most important artifact source in mpMRI interpretation. Prostate MRI should be planned at least 6-8 weeks after biopsy. Ideally, MRI should be performed BEFORE biopsy (pre-biopsy MRI approach). Hemorrhage resolves spontaneously and requires no treatment.